Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-01-16

Clinical Trial Update: Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers [EARLY_Phase 1]

View source ↗

Summary

This early Phase 1 trial evaluated the immunogenicity of intradermal Qdenga (TAK-003) dengue vaccine in healthy volunteers; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Qdenga (TAK-003)

Snippet

Sponsor: Prince of Songkla University | Conditions: Dengue | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2026-01-16